Abstract: The present invention relates to aromatic guanylhydrazone compounds and their use as pharmaceutically active agents, especially for prophylaxis and treatment of virally caused diseases and infections, including opportunistic infections. The inventive guanylhydrazone compounds are also useful as inhibitors of deoxyhypusine synthase and as inhibitors for nuclear export in infectious diseases and may be used to regulate bacterially induced TNF-? production. Furthermore, the aromatic guanylhydrazones exhibit antibacterial activity against Gram positive and Gram negative bacteria and can be regarded as a novel class of antibiotics. In addition, methods for prophylaxis and treatment of virally or bacterially induced infections and diseases are disclosed together with pharmaceutical compositions useful within said methods containing at least one aromatic guanylhydrazone of the present invention as active ingredient.

Abstract: The present invention relates to aromatic guanylhydrazone compounds and their use as pharmaceutically active agents, especially for prophylaxis and treatment of virally caused diseases and infections, including opportunistic infections. The inventive guanylhydrazone compounds are also useful as inhibitors of deoxyhypusine synthase and as inhibitors for nuclear export in infectious diseases and may be used to regulate bacterially induced TNF-&agr; production. Furthermore, the aromatic guanylhydrazones exhibit antibacterial activity against Gram positive and Gram negative bacteria and can be regarded as a novel class of antibiotics. In addition, methods for prophylaxis and treatment of virally or bacterially induced infections and diseases are disclosed together with pharmaceutical compositions useful within said methods containing at least one aromatic guanylhydrazone of the present invention as active ingredient.

Abstract: The subject of our invention is the process for the preparation of the 1-(3,4-dimethoxyphenyl)ethanol of formula (I), by the reduction of 3,4-dimethoxyacetophenone of formula (II), characterized in that the carbonyl group of the 3,4-dimethoxyacetophenone of formula (II) is reduced by 1 mol of hydrogen under the conditions of catalytic hydrogenation.

Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Abstract: The subject matter of the invention is the process for the preparation of mixed ethers of formula I, wherein Ar represents an aromatic or one or more heteroatom-containing moiety, optionally substituted by one or more C1-4 alkoxy, methylenedioxy, C1-4 alkyl, halogen, C1-4 haloalkyl or nitro-group, and/or condensed with a benzene ring; R1 and R2 independently mean hydrogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, phenyl, substituted phenyl, C3-6 cycloalkyl group, R3 means C3-6 alkynyl, optionally substituted by one or more C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C1-6 haloalkyl group, or halogen atom, R3 also means a C1-4 alkyloxy-C1-4 alkyloxy-C1-4 alkyl group.

Abstract: The invention relates to compounds of general formula (I), their optically active isomers and salts wherein Ar=alycylic, aromatic or one or more heteroatom containing heterocyclic moiety, optionally substituted by one or more alkoxy-, methylenedioxy-, alkyl-, halogen-, haloalkyl-,or nitro- group and/or condensed with a benzene ring. Ar—(CR1R2)m—(YR3R4)n—X—(CR5R6)o—(CR7R8)p—C≡C—E  (I) The compounds of general formula (I) according to the invention can be applied as active ingredients of pesticides, preferably arthropodicide compositions, and as synergists of other arthropodicideactive ingredients.

Abstract: Method and apparatus for long-term, non-invasive measuring of fetal heart rate. The method utilizes the characteristic curves of first and second heart sound received by the preferred electroacoustical converter. The identification and distinction of first and second sounds, furthermore their time relation used for heartbeat identification highly increase the reliability of fetal heart rate determination. The distinction of first and second sound is based on the differences in frequency spectrums measured in a relatively short time window and by the estimation of the power peaks measured on two test frequencies chosen on the two ends of the frequency range of fetal heart sound. The method is implemented in an integrated apparatus to achieve low power consumption for battery-operated long-term measurements. Digital filtering and selective power estimation is applied for continuous computation of power time function on the two test frequencies.

Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Abstract: The subject of the invention is an aqueous suspension containing: 0.1-20% by mass beta-cypermethrin, 0-40% by mass other pesticide substance, 1-10% by mass surface active substances in total and within this, 1-5% by mass ethoxylated polyaryl-phenol-phosphate or sulfate, 0.1-25% by mass mineral and/or synthetic silicates, 0.1-1% by mass synthetic silicic acid and up to 100% by mass other auxiliary materials and water as dispersant.

Abstract: Method for treating a patient inflicted with a cell proliferation disorder, such as a cancer, characterized by inappropriate PDGF-R activity. The method involves the step of administering to the patient a therapeutically effective amount of a composition described in application.

Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Abstract: The invention relates to novel 1,2-dihydro-1,2,4,5-tetrazine derivatives of the formula (IV) ##STR1## wherein means fluorine, chlorine or bromine; andY stands for hydrogen or fluorine,as well as to a process for the preparation thereof. The compounds according to the invention have acaricidal, larvicidal and ovicidal effects.

Abstract: The invention relates to novel tetrazine derivatives of the formula (I), ##STR1## wherein X is fluorine, chlorine or bromine; andY is hydrogen or fluorine, as well as to a process for the preparation thereof.Furthermore, the invention relates to compositions containing the above compounds as well as to a process for the preparation thereof. The compounds and compositions according to the invention have acaricidal; larvicidal an ovicidal effects.

Abstract: The invention relates to novel combined compositions for combatting plant, animal and sanitarian as well as forestry, horticultural and warehouse pests. These compositions contain a pyrethroid-type insecticide as an insecticidally active ingredient and at least one fungicide inhibiting the ergosterol biosynthesis as activity-strengthening agent as well as optionally piperonylbutoxide and other additives.The advantages of the compositions according to the invention consist therein that the activity-strengthening substances used are fungicidal agents widely used and have an advantageous toxicology. The activity-strengthening agent exerts a synergistic effect together with the pyrethroid-type insecticide.The combinations according to the invention bear an outstanding importance in the protection of stored crops.

Abstract: The invention relates to novel combined compositions for combatting plant, animal and sanitarian as well as forestry, horticultural and warehouse pests. These compositions contain a pyrethroid-type insecticide as an insecticidally active ingredient and at least one fungicide inhibiting the ergosterol biosynthesis as activity-strengthening agent as well as optionally piperonylbutoxide and other additives.The advantages of the compositions according to the invention consist therein that the activity-strengthening substances used are fungicidal agents widely used and have an advantageous toxicology. The activity-strengthening agent exerts a synergistic effect together with the pyrethroid-type insecticide.The combinations according to the invention bear an outstanding importance in the protection of stored crops.

Abstract: A pure crystalline O-(2-hydroxy-3-piperidino-1-propyl) nicotinic acid amidoxime base of the Formula (Ib) ##STR1## is disclosed characterized by a melting point of 70.degree. to 73.degree. C., giving, when dissolved in an amount of 1 to 10 ml of concentrated sulfuric acid, a yellow homogeneous solution, and showing the following spectral characteristics:IR spectrum (kBr): .gamma. --O--C.dbd.N 1642 cm.sup.-1.sup.1 H-NMR spectrum (CDCL.sub.3, .delta. ppm): 1.48 m, (6H), CH.sub.2 -piperidine; 2.42 m, (6H), 3.times.CH.sub.2 --N; 3.36, br, (1H), CH--O; 4.08 m, (3H), 1--CH.sub.2, OH; 5.2, br, (2H), NH.sub.2 ; 7.30 m (1H), pyridine-5'; 7.92 m, 4', 8.62 m (1H), 6', 8.88 m, (1H), 2'.

Abstract: The invention relates to a plant protecting or veterinary or additive composition, containing beside the active ingredient and other usually applied auxiliaries, such as solid and liquid carrier(s), surface active agent(s) and further additive(s), one or more surface active agent(s) of the general formulae (I) ##STR1## or a mixture thereof, wherein R, R.sup.2, R.sup.3 and R.sup.4 are independently from each other hydrogen atom, an organic or inorganic cation or a group of the general formula --(CH.sub.2 --CH.sub.2 --O).sub.n R.sup.1, whereinR.sup.1 is a C.sub.10-20 alkyl group andn is an integer from 4 to 20, with the provisio that from among the substituents R, R.sup.2 and R.sup.3 at least one is a group of the general formula (CH.sub.2 --CH.sub.2 O).sub.n R.sup.1.

Abstract: The inventions is a purer form of O-(2-hydroxy-3-piperidino-1-propyl)nicotinic acid amidoxime hydrochloride.

Abstract: A solution of a plant protective agent is disclosed, which comprises per liter of solution1 to 150 g/l of one or more synthetic pyrethroid(s) as active ingredient(s) and40 to 70 g/l of ethoxylated (EO=10 to 14)-propoxylated (PO)=18 to 22) nonylphenol,10 to 20 g/l of linear calcium dodecylbenzenesulfonate,90 to 120 g/l of polyoxyethylene(20)-sorbitan monolaurate as the surface active agents,and a solvent mixture (A) consisting of9 to 11% by volume of hydrogenated aliphatic hydrocarbon containing 45% of naphthene, 18 to 30% by volume of propylene glycol, 28 to 35% by volume of pine fatty acid, 23 to 30% by volume of sunflower oil, 5 to 10% by volume of an 1:1 by volume mixture of methanol or ethanol with isobutanol in an amount to complete the volume to 1 liter.